Corcept Therapeutics (CORT) Non Operating Income (2018 - 2026)

Corcept Therapeutics has disclosed Non Operating Income across 9 years of filings, most recently posting $4.9 million for Q1 2026.

• Non Operating Income for Q1 2026 came in at $4.9 million, down 21.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.3 million (down 19.4% YoY), and the FY2025 annual result was $21.7 million, down 11.72% from the prior year.
• Non Operating Income came in at $4.9 million for Q1 2026 at Corcept Therapeutics, down from $5.4 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $6.7 million in Q4 2024 to a low of $80000.0 in Q1 2022.
• The 5-year median for Non Operating Income is $5.0 million (2025), against an average of $4.2 million.
• Across the five-year window, Non Operating Income tumbled 70.91% in 2022 and surged 4376.25% in 2023, its largest moves.
• Corcept Therapeutics' Non Operating Income stood at $1.8 million in 2022, then soared by 189.25% to $5.1 million in 2023, then jumped by 30.31% to $6.7 million in 2024, then fell by 19.04% to $5.4 million in 2025, then declined by 9.9% to $4.9 million in 2026.
• The last three Non Operating Income figures came in at $4.9 million (Q1 2026), $5.4 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.